Trimeris will announce its most recently quarterly earnings after the markets close today.

Company stock closed down 3 percent, or $1.50, to close at $48.71.

Just last week, Prudential boosted its rating on Trimeris to “Buy”.
Trimeris stock hit $54.68 last week, up $5, after the company and Roche, its partner in the development and production of the AIDS drug Fuzeon, after announcing more encouraging data on the effectiveness of Fuzeon.